Abstract C39: First-in-class inhibitors of the putatively undruggable DNA repair target Poly(ADP-ribose) glycohydrolase (PARG)
Bohdan Waszkowycz(University of Manchester), Donald Ogilvie(Bioscience Research), Dominic I. James(AstraZeneca (United Kingdom)), Colin Hutton(The Francis Crick Institute), Sarah V. Holt(Pharma Nord (United Kingdom)), Alison E. McGonagle(Cancer Research UK Manchester Institute), James Hitchen(Cancer Research UK Manchester Institute), Alexandra Stowell(University of Manchester), Helen Small(University of Manchester), Allan M. Jordan(Signature Research (United States)), Ian D. Waddell(Charles River Laboratories (United Kingdom)), Emma Fairweather(University of Manchester), Nicola Hamilton(Cancer Research UK Manchester Institute), Ben Acton(Cancer Research UK Manchester Institute), Kate M. Smith(Cancer Research UK Manchester Institute), Stuart Jones(University of Manchester), Niall M. Hamilton(Ninewells Hospital), Sam Fritzl(Cancer Research UK Manchester Institute), Daniel P. Mould(University of Manchester)
Cited by 0
Related Papers
AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of Cancer
|Cancer Research|2005|710
Bub1 is required for kinetochore localization of BubR1, Cenp-E, Cenp-F and Mad2, and chromosome congression
|Journal of Cell Science|2004|344
Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia
|Nature Cancer|2021|279